Tag:
European Commission
Latest Headlines
Latest Headlines
EU antitrust officials probe parallel trade
EU investigators launched a probe into the players that buy drugs at cheap, state-regulated prices in lower-cost countries and resell them in markets where they can command higher prices.
EC drops antitrust probe aimed at GSK
European antitrust police are dropping another pharmaceutical probe. This time, the European Commission's competition regulator has stopped an investigation into GlaxoSmithKline ( $GSK ), Reuters reports. Officials had been looking into allegations GSK blocked generic competition for its drugs.
European regulators take steps to speed pricing, reimbursement decisions
The European Commission is taking steps to speed up national drug pricing and reimbursement decisions. Under a new proposal, such decisions should be made within 120 days for innovative medicines and 30 days for generic drugs. Currently, the time limit for both is 180 days.
EC antitrust squad drops AZ-Nycomed probe
AstraZeneca ( $AZN ) and Nycomed are in the clear, at least as far as European regulators are concerned. The European Commission's antitrust squad has dropped an investigation of the two companies...
Global Alzheimer's researchers seek cloud-based infrastructure to share data
With Alzheimer's disease threatening millions of patients worldwide, the European Commission-funded database that stores 3-D brain scans in the cloud has gained global attention. The so-called...
EU recruits first-ever chief scientific adviser from Scotland
Two years after pledging to create the position, European Commission President José Manuel Barroso has appointed Anne Glover, a Scottish molecular and cell biologist, as the region's
AstraZeneca wins EMA backing for thyroid cancer drug
AstraZeneca ( $AZN ) has gained support for its cancer drug vandetanib from European regulators, paving the way for a potential approval of the drug in the EU for advanced forms medullary thyroid
EC investigates J&J, Novartis over generic Fentanyl delay
Pharma giants Johnson & Johnson ( $JNJ ) and Novartis ( $NVS ) are being probed by EU antitrust regulators over concerns that they contractually arranged to delay the entry of a generic version of
Europe reviews rules on pharma-patient interaction
Drugmakers may soon be able to communicate more freely with European patients. The European Commission plans to review its policies restricting direct interaction with patients--and to draft new
Pfizer tops the charts in global R&D spending
It hasn't had a lot to show for it so far, but Pfizer became the world's number one spender on research and development last year, grabbing the top spot from Ford. The list, assembled by the
